Annotation Detail
Information
- Associated Genes
- SGK1
- Associated Variants
-
SGK1 OVEREXPRESSION
(
ENST00000367858.10 )
SGK1 OVEREXPRESSION ( ENST00000367858.10 ) - Associated Disease
- breast cancer
- Source Database
- CIViC Evidence
- Description
- A group of 18 breast cancer patients were treated with PI3Kalpha inhibitor alpelisib (NVP-BYL719) plus an aromatase inhbitor (NCT01870505). 3 out of 3 patients expressing high tumor SGK1 mRNA had disease progression as best response with median progression free survival (PFS) of 56 days, while 15 patients classified with low to medium SGK1 mRNA had median PFS 111 days with 4/15 having disease progression as best response.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1730
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5225
- Variant URL
- https://civic.genome.wustl.edu/links/variants/693
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Breast Cancer
- Evidence Direction
- Supports
- Drug
- Alpelisib
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 27451907
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Alpelisib | Resitance or Non-Reponse | true |